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Background: Pulmonary disease is a well recognised and important extra-articular manifesta-
tion of rheumatoid arthritis (RA). The objective of this study was to determine the prevalence
of airway and parenchymal abnormalities in newly diagnosed patients with RA and to correlate
these with clinical measures of RA severity and laboratory tests.
Methods: 60 patients with a new (symptom duration <12 months) diagnosis of RA (43 females,
42 European, mean age 54, 33 ever smoker, (17 current) underwent lung function testing and
high resolution computed tomography (HRCT) scored by two independent radiologists.
Results: Eighteen (30%) patients reported respiratory symptoms: dyspnoea (11), cough (11),
and wheeze (8). Twelve (20%) patients had physiologic evidence of airflow obstruction and
24 (40%) had reduced gas transfer. The prevalence of HRCT abnormalities (in any lobe) was
as follows: decreased attenuation 67%, bronchiectasis 35%, bronchial wall thickening 50%,
ground glass opacification 18%, reticular changes 12%. All abnormalities were more common
in the lower lobes. With the exception of reduced DLCO, there were no significant differences
in the prevalence of HRCT patterns or lung function parameters between smokers and non
smokers. Anti-CCP antibodies and rheumatoid factor (RF) correlated strongly with DLCO and
variably with other physiologic measures but poorly with radiologic abnormalities.Respiratory Services, Auckland District Health Board, Private Bag 92 024, Wellesley St, Auckland, New
4 9 631 0712.
vt.nz (M. Wilsher).
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1442 M. Wilsher et al.Conclusion: Patients with newly diagnosed RA have a moderate prevalence of airway and
parenchymal abnormalities on HRCT and lower than predicted lung function parameters which
cannot entirely be explained by smoking. These data suggest that pulmonary involvement is
present early in the disease course in RA.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Pulmonary disease is a well recognised and important
extra-articular manifestation of rheumatoid arthritis (RA)
with autopsy studies suggesting that it is the second most
common cause of death after infections.1 Although the
focus has been on interstitial disease there is increasing
recognition of airway involvement. Such manifestations are
usually recognised late in the course of the disease,
possibly because respiratory involvement has a sub-clinical
phase as the patient may well be limited by articular
disease.2
It is not clear whether all of the pulmonary manifesta-
tions of RA are present at the outset or indeed precede the
articular manifestations of the disease. Gabbay et al.
reported radiologic or bronchoalveolar lavage abnormali-
ties consistent with interstitial lung disease in 21 of 36
patients with newly diagnosed RA but made no comment on
airways disease.3 More recently Mori et al. performed lung
function and high resolution computed tomography (HRCT)
in 65 Japanese patients with recent onset RA and found
a high proportion of patients with bronchial dilatation
(33.8%) and bronchial wall thickening (6.2%) together with
features of interstitial disease.4 Associations between
pulmonary disease and serological measures or rheumatoid
clinical parameters have not been clearly established.
The aims of this study were to determine the prevalence
of airway and parenchymal abnormalities in newly diag-
nosed RA patients and whether these correlate with clinical
measures of RA severity and laboratory parameters.Methods
Patients and clinical assessments
Sixty patients, age 18 years, with newly diagnosed RA
(symptoms less than one year) were consecutively recruited
from the rheumatology clinic of a major teaching hospital.
All patients met the 1987 ARA classification criteria for RA,5
and all had the following assessments recorded:
1) Rheumatology and respiratory symptoms, medications
and smoking history.
2) Examination of the respiratory and musculoskeletal
systems
3) Laboratory testing including C-reactive protein (CRP),
rheumatoid factor by ELISA, and anti-cyclic citrulli-
nated peptides (CCP) (INOVA, 2nd generation).
4) The DAS28-ESR (4 variables with erythrocyte sedimen-
tation rate (ESR)), a composite measure of RA inflam-
matory disease activity.6Lung function testing
Spirometric and plethysmographic lung volumes together
with DLCO were measured by the single breath technique as
previously described and according to the American
Thoracic Society Guidelines using European Community
Coal and Steel (ECCS) reference values.7e9 Results are
expressed as percent predicted.
High resolution computed tomography
Studies were performed using a Prospeed Advantage CT
scanner, GE Medical Systems, Milwaukee, Wis. One milli-
metre collimation scans were performed at 10 mm intervals
at full inspiration. Limited further inter-spaced sections
were performed at end expiration. The CT scans were
assessed in random order, by two experienced observers
(DM, MT), without knowledge of clinical findings or lung
function tests. The HRCT images were scored using
a modified Bhalla scoring system.10,11 This is a lobar analysis
of severity and extent of bronchiectasis with additional
scoring of large airways wall thickness, the presence of
small and large airways mucus plugging, emphysema and
decreased attenuation. The extent and severity of bron-
chiectasis and the degree of bronchial wall thickening are
each scored on a 4 point scale, the extent of small airways
mucus plugging, emphysema and decreased attenuation
(pulmonary lobules or conglomerates of pulmonary lobules
which are reduced in density) was scored to the nearest 5%
of the lobe involved. Large airways mucus plugging was
described as either present or absent for each lobe. The
lingula was described as a separate lobe giving a set of 6
lobar scores for each patient. The scoring system for
interstitial abnormalities was a numerical semiquantitative
lobar extent score based on quartile of whole lobe
involvement for each of ground glass opacity, reticulation
and consolidation.12
Statistical evaluation
Continuous data were summarised as mean values (SD) if
normally distributed or as median (range) if skewed.
Categorical data were summarised as frequency and
percentage. For continuous data, comparisons between
groups were performed by the Student’s t test or Man-
neWhitney U test where appropriate. Categorical data
were compared using the two proportions Z test. Inter-
relationships between variables were evaluated using
Spearman’s nonparametric rank correlation analysis. To
adjust for confounding (smoking status) in the correlation
analysis, Spearman’s partial nonparametric correlation
Lung involvement in newly diagnosed RA 1443coefficient was calculated. Weighted Kappa coefficients
were calculated to quantify the agreement between two
independent researchers’ for each of the four HRCT
patterns. A P value <0.05 was considered to be statistically
significant. The SAS statistical package version 9.2 was used
for analysis (SAS Institute Inc., Cary, NC, USA).
Approvals
This study had the approval of the New Zealand Ministry of
Health Northern Regional Ethics Committee (Approval
number AKX/02/01/005) and the Auckland District Health
Board Research Office. All patients provided written
informed consent.
Results
Clinical characteristics
The patient characteristics are summarised in Table 1.
Patients were predominantly middle aged females of
European ancestry with median symptom duration of 7
months. Disease activity was moderately high, and the
majority of patients were seropositive for rheumatoid
factor and anti-CCP antibodies. All but two patients had
taken or were currently taking disease-modifying anti-
rheumatic drugs (DMARDs) at the time of study although
none were taking biologic agents. Eight patients had
a history of asthma (either past or current) but only two had
abnormal lung function; one had an FEV1 83% predicted andTable 1 Clinical characteristics of 60 patients with newly
diagnosed RA.
Clinical characteristics
Age (years), median (range) 54 (26e76)
Symptom duration (months), median (range) 7 (1e12)
Gender, n (%)
Male 17 (28%)
Female 43 (72%)
Ethnicity, n (%)
European 42 (70%)
Maori 5 (8%)
Pacific Islander 4 (7%)
Indian 3 (5%)
Asian 2 (3%)
Other 4 (7%)
Smoking history, n (%)
Non-smoker 27 (45%)
Ex-smoker 15 (25%)
Current smoker 17 (28%)
Ever smoked but unknown current status 1 (2%)
Medications, n (%)
Methotrexate 39 (65%)
Prednisone 35 (58%)
DAS28-ESR, median (range) 4.6 (0.7e7.3)
C-reactive protein (mg/L), median (range) 3 (0.5e97)
Rheumatoid factor positive 43/60 (72%)
Anti-CCP antibody positive 43/52 (80%)the other, a non-smoker, had chronic airflow limitation with
FEV1 44%. Four of those patients reported current respira-
tory symptoms including the two with abnormal FEV1
measurements. Three patients self reported a diagnosis of
COPD, one being the same non-smoking patient with
asthma and FEV1 of 44%, and the other two asymptomatic
smokers with mild physiologic impairment (FEV1 of 74% and
85% predicted respectively). No patients reported a history
of bronchiectasis, interstitial lung disease or emphysema.
Respiratory symptoms and lung function
Less than one third of patients had any respiratory symp-
toms despite a moderate prevalence of physiologic abnor-
malities (Table 2). One fifth had evidence of airflow
limitation (FEV1/VC ratio <70%) and 40% had depression of
gas transfer. There were no significant differences between
smokers and non-smokers with respect to respiratory
symptoms or lung function parameters, except for lower
DLCO in smokers. The median lung function results did not
change after excluding the 10 patients with either a history
of asthma or COPD although the inter-quartile ranges
narrowed.
HRCT patterns
A number of HRCT patterns were observed (Table 2). There
was very good agreement between the radiologists with
kappa statistics ranging from 0.64 to 0.78 for the individual
radiologic patterns. The most common abnormality was
decreased attenuation which was present in two-thirds of
patients. Eleven (18%) patients had decreased attenuation
of greater than 20% in one or more lobes, which would be
considered clinically abnormal. Less frequent HRCT abnor-
malities were bronchiectasis and bronchial wall thickening.
One patient had bronchial dilatation and two had bronchial
wall thickening scores of 2 or greater and 12 (20%) patients
had bronchiectasis extent scores of 2 or 3 e parameters
that would be considered clinically significant. Paren-
chymal abnormalities were less common. All abnormalities
were more common in the lower lobes. There were no
significant differences between smokers and non smokers in
relation to these patterns.
Relationships between respiratory symptoms. Lung
function tests and HRCT patterns
Lung function parameters correlated modestly with CT
features of airways disease including bronchial wall thick-
ening, and extent and severity of bronchiectasis (Table 3).
However, there was no association between CT patterns of
interstitial disease (ground glass opacification and reticular
changes) and lung function. Furthermore, there was no
relationship between lung function parameters and respi-
ratory symptoms (data not shown). Similarly, there was no
relationship between HRCT patterns and respiratory
symptoms, with the exception of an association between
dyspnoea and bronchiectasis; patients reporting dyspnoea
had higher median HRCT scores for bronchiectasis extent (4
vs. 0, pZ 0.01) and severity (2 vs. 0, pZ 0.02), compared
with those without dyspnoea.
Table 2 Respiratory symptoms, lung function tests and HRCT patterns.
Overall (n Z 60) Previous/current
smoker (n Z 33)
Non-smoker
(n Z 27)
P-value
Number with respiratory symptoms, n (%)
Any symptoms 18 (30%) 12 (36%) 6 (22%) 0.23
Dyspnoea 11 (18%) 5 (15%) 6 (22%) 0.52
Cough 11 (18%) 8 (24%) 3 (11%) 0.31
Cough with sputum 11 (18%) 9 (27%) 2 (7%) 0.09
Wheeze 8 (13%) 6 (18%) 2 (7%) 0.28
Lung function, median (range)
FEV1% 96 (48e131) 98.5 (48e131) 95 (49e123) 0.51
VC% 93 (57e130) 93 (57e130) 92.5 (60e127) 0.74
FEV1/VC ratio 0.76 (0.37e0.89) 0.77 (0.54e0.86) 0.76 (0.37e0.87) 0.60
DLCO% 85 (53e143) 78 (53e143) 86 (61e109) 0.10
Number with abnormal lung function parameters, n (%)
FEV1<80% predicted 15 (25%) 7 (21%) 8 (30%) 0.45
VC<80% predicted 15 (25%) 6 (18%) 9 (33%) 0.18
FEV1/VC ratio<70% 12 (20%) 7 (21%) 5 (19%) 0.80
DLCO <80% predicted 24 (40%) 18 (55%) 6 (22%) 0.01
HRCT patterns, n (%)
Decreased attenuation 49 (82%) 27 (82%) 22 (81%) 0.97
Bronchiectasis 29 (48%) 18 (55%) 11 (41%) 0.29
Bronchial wall thickening 35 (58%) 19 (58%) 16 (59%) 0.90
Ground glass opacification 14 (23%) 12 (36%) 2 (7%) 0.01
Reticular changes 11 (18%) 8 (24%) 3 (11%) 0.19
Dense consolidation 4 (7%) 1 (3%) 3 (11%) 0.21
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measures
There was no significant correlation between lung function
parameters or HRCT abnormalities and RA inflammatory
disease activity, as measured by the DAS28-ESR. However,
there were associations between serological and pulmonary
measures (Table 4). In particular, the concentration of anti-
CCP antibodies correlated with reduced lung volumes and
impaired gas transfer (DLCO), and with the pattern of bron-
chial wall thickening on HRCT. Rheumatoid factor concen-
tration only correlated with the physiologic measure DLCO,
and on HRCT with the parenchymal pattern of ground glass
opacification suggesting this serological measure may asso-
ciate with interstitial injury in RA. There was a modest
correlation between CRP and bronchial wall thickening on CT
(rZ 0.34, p < 0.03), and with DLCO (rZ 0.32, p < 0.05).Table 3 Correlation between lung function parameters and HR
Lung function HRCT Pattern
Spearman partial correlation coefficients (p-v
Decreased
Attenuation
Extent of
Bronchiectasis
Severity of
Bronchiectasis
FEV1% predicted 0.15 (0.27) 0.21 (0.13) 0.21 (0.12)
FVC % predicted 0.18 (0.20) 0.29 (0.03) 0.28 (0.04)
FEV1/VC ratio 0.12 (0.37) 0.06 (0.65) 0.08 (0.56)
DLCO % predicted 0.15 (0.26) 0.13 (0.36) 0.14 (0.31)
a adjusted for cigarette smoking.Discussion
This study demonstrates a moderate prevalence of airway
and parenchymal abnormalities in patients with newly
diagnosed RA, despite a relative paucity of symptoms and
irrespective of smoking history. These pulmonary abnor-
malities do not associate with global measures of RA
inflammatory disease activity but both lung function and
HRCT parameters exhibit moderate albeit variable associ-
ations with serological markers.
Although parenchymal lung abnormalities have been
reported, the presence of airways disease in patients with
newly diagnosed RA is a novel finding of this study.3
Previous studies have demonstrated that airways disease
is evident on HRCT in up to a third of patients with estab-
lished RA and the prevalence appears to be higher in
patients with longstanding disease.4,13,14 This study hasCT patterns.
alue)a
Bronchial
Wall
Thickening
Ground
Glass Opacity
Reticular
Density
Dense
Consolidation
0.43 (<0.01) 0.11 (0.43) 0.08 (0.57) 0.13 (0.34)
0.32 (0.02) 0.08 (0.58) 0.13 (0.36) 0.15 (0.27)
0.35 (0.01) 0.07 (0.63) 0.02 (0.89) 0.17 (0.21)
0.29 (0.03) 0.22 (0.11) 0.16 (0.25) 0.20 (0.15)
Table 4 Correlation between serological and pulmonary
measures.
Serological measure
Spearman Partial Correlation
Coefficients (p-value)
Anti-CCP
concentration
(units)
Rheumatoid
factor (kIU/L)
Lung functiona
FEV1% predicted 0.42 (0.01) 0.26 (0.11)
FVC % predicted 0.37 (0.02) 0.18 (0.27)
FEV1/VC ratio 0.16 (0.34) 0.23 (0.17)
DLCO % predicted 0.59 (<0.01) 0.45 (0.01)
HRCT patterna
Bronchial wall thickening 0.28 (0.05) 0.04 (0.79)
Ground glass opacityb 0.22 (0.12) 0.31 (0.03)
a Adjusted for cigarette smoking.
b No other CT measures showed significant associations with
serology.
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present early in the course of the disease despite the
patients being asymptomatic or having few respiratory
symptoms. Although the severity of the airway abnormali-
ties was relatively mild, a significant proportion of patients
had bronchiectasis affecting at least two lobes and/or
radiologic evidence of air trapping (decreased attenuation
on HRCT).
Whilst many studies report the prevalence of radiologic
abnormalities in asymptomatic or symptomatic patients
with RA, few have examined associations with physiologic
parameters. Although it appears that there are relation-
ships between physiologic measures of airflow limitation
and morphologic features of airways involvement, it is not
always clear whether this is independent of the impact of
cigarette smoking which is variably taken into
account.4,15,16 Data from this study reveal positive associ-
ations between morphologic and physiologic parameters of
pulmonary disease in patients with newly diagnosed RA,
and these exist independently of smoking history. However,
the finding of a low DLCO and the HRCT pattern of ground
glass opacification (albeit a non significant association) in
more smokers than non smokers does raise the possibility
that some of the smokers have respiratory bronchiolitis-
interstitial lung disease (RBILD), an smoking related inter-
stitial process independent of RA.
Of particular interest are the differential associations
observedbetweenanti-CCPantibodies and rheumatoid factor
in relation to lung function and HRCTabnormalities. Anti-CCP
antibodies are highly specific for RA and are associated with
poor articular prognosis.17,18 Consistent with most other
studies in RA,19,20 we have not identified a relationship
between anti-CCP antibodies and HRCT features of RA-ILD.
However, our study has demonstrated a novel association
between anti-CCP antibodies and both physiologic abnor-
malities and bronchial wall thickening on HRCT suggesting
that this antibody is associated with an RA related respiratory
insult. The important interaction between cigarette smokingand anti-CCP antibodies may be of relevance, noting that
tobacco exposure (which induces citrullination of proteins)
increases the risk of anti-CCP antibodies in shared epitope
positive patients with RA.21 However, even after adjusting
statistically for cigarette smoking, we observed a persistent
association between anti-CCP antibodies and physiologic or
HRCT abnormalities, suggesting that this association cannot
be explained by cigarette smoking alone. In contrast to anti-
CCP antibodies, our results suggest a weak association
between rheumatoid factor and parenchymal lung disease in
RA, as indicated by depression of gas transfer and extent of
ground glass opacity on HRCT.
Neither lung function abnormalities nor HRCT patterns
of disease associate with global measures of RA inflamma-
tory disease activity. This apparent dislocation between
measures of articular involvement and other organ system
involvement has been reported previously, albeit not in
early RA.22 A further key finding of our study is that respi-
ratory symptoms are an unreliable guide to the presence or
absence of RA associated pulmonary disease. Our results
are not sufficiently compelling to support routine screening
for respiratory disease in newly diagnosed RA because
despite the high prevalence of CT abnormalities the
severity and extent of such was relatively minor in the
majority of patients and there was a poor correlation with
pulmonary function measures or respiratory symptoms
What is unknown is the significance of these changes.
Currently there are no published longitudinal studies of
patients with early RA demonstrating the natural history of
baseline pulmonary abnormalities, or the role of autoanti-
bodies in progression of RA associated pulmonary disease.
Furthermore, it is unknown whether intensive treatment of
RA using nonbiological or biological disease modifying anti-
rheumatic drugs (DMARDs) or other interventions alter
progression of lung disease in RA. Such studies are required
to guide the type and frequency of surveillance for the
pulmonary manifestations of RA.
This study has a number of limitations: the number of
patients studied is relatively small and eight had prior respi-
ratory disease, albeit mild in all but one. Although we have
adjusted our analyses for smoking history an ideal cohort
would consist of nonsmokers. Additionally, almost the entire
cohort had taken or was currently taking DMARDs at the time
of study and that may have influenced the prevalence of
respiratory abnormalities and the CRP. None the less, and
notwithstanding the high prevalence of smoking, the lung
would appear to be susceptible to rheumatoid associated
injury early in the course of the disease. However, the clinical
significance of the findings remain unclear and can really only
be answered with a longitudinal cohort.
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